Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults.
OBJECTIVE
To investigate the effect of three weeks' intervention with a probiotic Lactobacillus rhamnosus GG (LGG) bacteria on global serum lipidomic profiles and evaluate whether the changes in inflammatory variables (CRP, TNF-alpha and IL-6) are reflected in the global lipidomic profiles of healthy adults.


METHODS
We performed UPLC/MS-based global lipidomic platform analysis of serum samples (n = 26) in a substudy of a randomised, double-blind, placebo-controlled 3-wk clinical intervention trial investigating the immunomodulatory effects of probiotics in healthy adults.


RESULTS
A total of 407 lipids were identified, corresponding to 13 different lipid classes. Serum samples showed decreases in the levels of lysophosphatidylcholines (LysoGPCho), sphingomyelins (SM) and several glycerophosphatidylcholines (GPCho), while triacylglycerols (TAG) were mainly increased in the probiotic LGG group during the intervention. Among the inflammatory variables, IL-6 was moderately associated by changes in global lipidomic profiles, with the top-ranked lipid associated with IL-6 being the proinflammatory LysoGPCho (20:4). There was a weak association between the lipidomic profiles and the two other inflammatory markers, TNF-alpha and CRP.


CONCLUSIONS
This was the first study to investigate the effects of probiotic intervention on global lipidomic profiles in humans. There are indications that probiotic LGG intervention may lead to changes in serum global lipid profiles, as reflected in decreased GPCho, LysoGPCho and SM as well as mainly increased TAG.
University of Helsinki, Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki 00014, Finland.
Riina-A
RA
Kekkonen
Marko
M
Sysi-Aho
Tuulikki
T
Seppanen-Laakso
Ilkka
I
Julkunen
Heikki
H
Vapaatalo
Matej
M
Oresic
Riitta
R
Korpela
D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D002853:Chromatography, Liquid; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D052201:Lacticaseibacillus rhamnosus; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage*; D012016:Reference Values; D021241:Spectrometry, Mass, Electrospray Ionization; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
C508600:IL6 protein, human; D015850:Interleukin-6; D008055:Lipids; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein